La vendita allo scoperto per Alumis dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Alumis. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Alumis (NASDAQ:ALMS) Azioni, Report sulle vendite allo scoperto

ALUMIS INC

Alumis

Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Company pipeline includes: ESK-001, TYK2, A-OO5, IRF5.

wall street chart shutter2

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ALMS

CMRX

DERM

Analisi dei segnali di allarme nel settore sanitario: cosa rivela l&#39;indicatore tecnico chiave per gli investitori. È il momento di agire?

3 titoli del settore sanitario che potrebbero crollare nel secondo trimestre

Alumis Inc

10X Research has identified a historically consistent warning sign of a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) bear market now flashing red: the widening of <a href="https://www.benzinga.com/money/corporate-bonds-guide">U.S. corporate credit spreads</a>.
What Happened: According to the firm's latest analysis, the year-on-year change in the ICE BofA BBB U.S. Corporate Index Option-Adjusted Spread has turned positive—an event that has reliably marked the beginning of Bitcoin downturns in past cycles.
"When credit spreads begin to widen—as they are now—it's typically a signal that the correction in risk assets is far from over," the report stated. 
The rise in the corporate credit spread suggests tightening liquidity and growing credit risk, both of which have historically pressured crypto markets.
The firm emphasizes that this signal isn't noise. 
It has preceded all previous major Bitcoin bear markets. With spreads now climbing, the implication is that investors should brace for continued downside, rather than bet on a near-term recovery.
10X Research argues this shift coincides with broader macro uncertainty, including tariff-induced volatility, deteriorating shipping demand, and shifting consumer behavior. 
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44697921/shiza-launches-open-beta-for-drag-and-drop-agentic-ai-workflow-builder">SHIZA Launches Open Beta For Drag-And-Drop Agentic AI Workflow Builder</a>
Why It Matters: Combined, these conditions may create the perfect environment for a deeper risk-off move across equities and digital assets.
"Bitcoin has already broken below its 21-week moving average near $89,000," the firm noted, referring to a key trendline that often signals downside momentum when breached. 
Prices have since hovered around $77,000, and 10X Research suggests a test of $73,000—or even $60,000—is increasingly plausible.
While some market participants interpreted recent White House talk of a "90-day truce" with China as a sign of de-escalation, the report cautions against overconfidence. 
"Many investors were lured into buying the dip, placing too much faith in reassuring statements from Trump and Bessent," analysts wrote. "But the data is telling a different story."
10X Research argues that pressure is not just building in risk assets, but also in the foundation of the financial system. 
"The sharp decline in 3-year SOFR swap spreads signals rising stress in bank funding markets," the report adds, warning of a potential domino effect across credit and liquidity channels.
Given these conditions, 10X suggests it's premature to expect a recovery in either crypto or equities. 
"This is not the moment to step in," the team concluded, referencing its previous warnings.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44696653/how-bitcoin-will-go-from-65000-to-225000-in-2025">How Bitcoin Will Go From $65,000 To $225,000 In 2025</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Widening Credit Spreads Signal Potential Bitcoin Bear Market, 10X Research Warns

D. Boral Capital analyst Jason Kolbert maintains FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) with a Buy and maintains $16 price target.

Price Target

Analyst Ratings

FBLG

D. Boral Capital Maintains Buy on FibroBiologics, Maintains $16 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar initiates coverage on vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) with a Buy rating and announces Price Target of $36.

Initiation

VTVT

HC Wainwright & Co. Initiates Coverage On vTv Therapeutics with Buy Rating, Announces Price Target of $36

D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) with a Buy and maintains $30 price target.

IBRX

D. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target

Goldman Sachs analyst Asad Haider upgrades Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) from Neutral to Buy and raises the price target from $157 to $172.

Upgrades

Goldman Sachs Upgrades Johnson & Johnson to Buy, Raises Price Target to $172

HC Wainwright &amp; Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) with a Buy and lowers the price target from $6 to $4.

CASI

HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $4

Evercore ISI Group analyst Adam Frisch initiates coverage on PayPal Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) with a In-Line rating and announces Price Target of $65.

PYPL

Evercore ISI Group Initiates Coverage On PayPal Holdings with In-Line Rating, Announces Price Target of $65

DPRO

Draganfly Have Been Selected As The Primary UAS Provider By Balko Technologies For Integration Of Advanced Modular LiDAR Drone Solutions

Evercore ISI Group analyst Adam Frisch initiates coverage on Global Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) with a In-Line rating and announces Price Target of $85.

Evercore ISI Group Initiates Coverage On Global Payments with In-Line Rating, Announces Price Target of $85

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) with a Buy and maintains $720 price target.

Reiteration

ARGX

HC Wainwright & Co. Reiterates Buy on argenx, Maintains $720 Price Target

Macro Economic Events

Economics

China Commerce Ministry Said Adds 12 U.S. Entities to Export Control List

Evercore ISI Group analyst Adam Frisch initiates coverage on Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a In-Line rating and announces Price Target of $52.

Evercore ISI Group Initiates Coverage On Block with In-Line Rating, Announces Price Target of $52

D. Boral Capital analyst Jason Kolbert maintains MediciNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNOV#NASDAQ">MNOV</a>) with a Buy and maintains $9 price target.

MNOV

D. Boral Capital Maintains Buy on MediciNova, Maintains $9 Price Target

Evercore ISI Group analyst Adam Frisch initiates coverage on Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a In-Line rating and announces Price Target of $29.

TOST

Evercore ISI Group Initiates Coverage On Toast with In-Line Rating, Announces Price Target of $29

HC Wainwright &amp; Co. analyst Amit Dayal maintains FTC Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) with a Buy and raises the price target from $1.5 to $5.

FTCI

HC Wainwright & Co. Maintains Buy on FTC Solar, Raises Price Target to $5

Evercore ISI Group analyst Adam Frisch initiates coverage on Shift4 Payments (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) with a In-Line rating and announces Price Target of $80.

FOUR

Evercore ISI Group Initiates Coverage On Shift4 Payments with In-Line Rating, Announces Price Target of $80

Guidance

TRNR

Interactive Strength Raised 2025 Pro Forma Revenue By 30% To More Than $65M

D. Boral Capital analyst Jesse Sobelson maintains EON Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/EONR#AMEX">EONR</a>) with a Buy and maintains $4.5 price target.

EONR

D. Boral Capital Maintains Buy on EON Resources, Maintains $4.5 Price Target

On Tuesday, April 8th, U.S. markets closed sharply lower as the S&amp;P 500 plunged below 5,000 for the first time in nearly a year, capping a four-day loss of $5.83 trillion—the steepest since the index&#8217;s inception in the 1950s. Early gains evaporated as hopes for delayed U.S. tariffs faded, and looming 104% duties on Chinese goods fueled mounting fears of a global economic downturn.
In economic data, the NFIB Small Business Optimism Index fell by 3.3 points to 97.4 in March, marking its lowest level since October 2024 and missing expectations of 101.3.
All sectors within the S&amp;P 500 ended Tuesday in the red, with consumer discretionary, materials, and energy stocks leading the day&#8217;s declines.
The Dow Jones Industrial Average declined 0.84% to 37,645.59, the S&amp;P 500 dropped 1.57% to 4,982.77, and the Nasdaq Composite fell 2.15% to close at 15,267.91.
Asia Markets Today
<ul>
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed 3.78% lower at 31,764.00, led by losses in the Paper &amp; Pulp, Transport, and Communication sectors amid trade war fears, tech stock losses, a rising yen, and widespread panic selling. Nearly 90% of stocks declined as investors grappled with sharp volatility and deepening global economic uncertainty.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 was down 1.80% and closed at 7,375.00, led by losses in the Energy, Metals &amp; Mining and Resources sectors.</li>
<li>India&#8217;s Nifty 50 was down 0.59% to 22,402.45, and Nifty 500 slid 0.57% to 20,363.10.</li>
<li>The RBI cut interest rates by 25 basis points to 6% and shifted to an &#8220;accommodative&#8221; stance, citing easing inflation and slowing growth. GDP forecast was lowered amid global trade tensions.</li>
<li>China&#8217;s Shanghai Composite rose 1.31% to 3,186.81, and Shanghai Shenzhen CSI 300 increased 0.99% to 3,686.79.</li>
<li>Hong Kong&#8217;s Hang Seng Index gained 0.68% to 20,264.49.</li>
</ul>
Eurozone at 05:45 AM ET
<ul>
<li>The European STOXX 50 was down 2.77%.</li>
<li>Germany&#8217;s DAX declined 2.85%.</li>
<li>France&#8217;s CAC 40 fell 2.77%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 2.50%.</li>
<li>European shares fell sharply on Wednesday as steep U.S. tariffs reignited trade war concerns, dragging markets lower and pushing the STOXX 600 closer to bear territory. Rate-sensitive banks, pharmaceutical giants, energy and mining stocks led the decline.</li>
</ul>
Commodities at 05:45 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 3.89% at $57.25/bbl, and Brent was down 3.82% at $60.42/bbl.</li>
<li>Oil prices fell to a multi-year low Wednesday, marking their worst five-day losing streak in years. Global recession fears deepened amid escalating U.S.-China trade tensions and rising supply outlooks.</li>
<li>Natural Gas rose 0.55% to $3.482.</li>
<li>Gold was trading higher by 2.44% at $3,062.64, Silver was up 2.12% to $30.320, and Copper rose 2.21% to $4.2355.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.40%, S&amp;P 500 futures declined 0.22%, and Nasdaq 100 futures rose 0.21%.
Forex at 05:45 AM ET
<ul>
<li>The U.S. Dollar Index declined 0.64% to 102.31, USD/JPY was down 0.70% to 145.23, and USD/AUD declined 0.95% to 1.6626.</li>
<li>The U.S. dollar slumped after President Trump&#8217;s steep tariff hike on China intensified recession fears. Markets now expect deeper Federal Reserve rate cuts, pressuring the greenback. The Dollar Index fell to levels not seen since September 2024, while safe-haven currencies like the yen and euro strengthened.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

China Markets Up, Europe Tumbles As Trade War Escalates; Oil Hits Multi-Year Low - Global Markets Today While US Slept

As at March 31st, 2025, Osisko's cash position was approximately $63.1 million, following a $19.6 million net repayment on the Company's revolving credit facility during the first quarter. Osisko's revolving credit facility was drawn by $74.3 million at the end of March 2025, with an additional amount of $308.2 million available to be drawn plus the uncommitted accordion of C$200 million.
 &nbsp;

Osisko Gold Royalties Says It Earned 19,014 Attributable Gold Equivalent Ounces In Q1, Company Recorded Preliminary Revenues From Royalties And Streams Of $54.9M

Health Care

Press Releases

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout

ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger

Comments

Alumis

Vendite allo scoperto

Alumis (NASDAQ:ALMS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO